ONO-4538 + Oxaliplatin + Tegafur- Gimeracil-Oteracil potassium + Capecitabine + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Mar 1, 2016 → Nov 17, 2022
NCT ID
NCT02746796About ONO-4538 + Oxaliplatin + Tegafur- Gimeracil-Oteracil potassium + Capecitabine + Placebo
ONO-4538 + Oxaliplatin + Tegafur- Gimeracil-Oteracil potassium + Capecitabine + Placebo is a phase 2/3 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02746796. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02746796 | Phase 2/3 | Completed |
Competing Products
20 competing products in Gastric Cancer